Evidence map›Paper›PMID 18665399›Full record

ArticleJournal of molecular modeling2008

Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design.

Abhay T Sangamwar, Leena B Labhsetwar, Sharad V Kuberkar

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.Bioinorganic chemistry and applications · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Abhay T SangamwarDepartment of Pharmaceutics, Nanded Pharmacy College, Shyamnagar, Nanded, 431605 MS, India. abhaysangamwar@yahoo.co.in
Leena B Labhsetwar
Sharad V Kuberkar
Sanskriti Samvardhan Mandal · INGovernment Ayurved College, Nanded · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsomal cytochrome P450 family 1 enzymes has great importance in the bioactivation of mutagens. P450 catalyzed reactions involve a wide range of substrates, and this versatality is reflected in a structural diversity, evident in the active sites of available P450 structures. This structure offers a template to study further structure-function relationships of alternative substrates and other cytochrome P450 family 1 members. In this paper, we document a homology model of CYP P450 1A1 from Homo sapiens, developed on the basis of template crystal structure of human microsomal P450 1a2 in complex with inhibitor (PDB Id: 2HI4). Homology modeling is performed at the programs, both in the commercial and public realms. We tried to explore CYP1A1 as a potential target for anticancer chemotherapy. To gain an insight into the binding of ligands with enzyme, protein-ligand complex was developed by including information about the known ligand as spatial restraints and optimizing the mutual interactions between the ligand and the binding site. Active site characterization and the study for involvement of specific aminoacids in binding with ligand, facilitates structure based inhibitor design. This study should prove useful in the design and development of potential novel anticancer agents.

Indexed as

Amino Acid SequenceAntineoplastic AgentsBinding SitesCatalytic DomainCrystallography, X-RayCytochrome P-450 CYP1A1Drug DesignHumansLigandsModels, MolecularMolecular Sequence DataSequence AlignmentSequence Homology, Amino AcidAntineoplastic AgentsCytochrome P-450 CYP1A1Ligands

Identifiers

PMID18665399
OpenAlexW2008244096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.